跳至主要内容
临床试验/NCT03379389
NCT03379389已完成4 期

Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis

Fundação Educacional Serra dos Órgãos1 个研究点 分布在 1 个国家目标入组 284 人开始时间: 2018年3月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
284
试验地点
1
主要终点
Urination regularity

研究概览

简要总结

This is a double-blind, randomized, double-dummy, comparative study in parallel groups of subjects presenting with recurrent cystitis (≥2 episodes within the past 6 months). Subjects will be randomized and treated with one of two presentations of urinary antiseptics containing methenamine and methylthioninium for three days, followed by three days of antibiotic therapy as determined by urine culture and antibiogram. This study aims to assess the efficacy and safety of each treatment.

详细描述

This is a double-blind, randomized, double-dummy, comparative study in parallel groups of subjects presenting with recurrent cystitis (≥2 episodes within the past 6 months). After initial evaluations including urine culture and antibiogram, a total of 284 subjects will be randomized and treated with one of two presentations of urinary antiseptics containing methenamine and methylthioninium for six days. After three days of treatment, subjects will return to the study center and antibiotic therapy based on the results of the urine culture and antibiogram will be initiated for each subject, to be continued for the remaining three days of the treatment period. Efficacy assessments will include the UTISA (Urinary Tract Infection Symptoms Assessment Questionnaire) together with a global assessment by the investigator. Safety assessments will include monitoring of adverse events and laboratory tests carried out at each of the three study visits.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of both sexes, age ≥18
  • Clinical diagnosis of recurrent cystitis (≥ 2 episodes in the past 6 months)
  • Female subject of reproductive age not pregnant, agrees to use birth control during study period
  • Subject has read, understood, signed and dated informed consent document

排除标准

  • History of nephritis or kidney stones
  • History of hepatic or gastrointestinal disease
  • Female subjects: pregnancy or breastfeeding
  • History of anatomical alterations contributing to recurring cystitis on imaging exams
  • Hypersensitivity to any component of study drug

研究组 & 干预措施

Methenamine + Methylthioninium

Experimental

Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days

干预措施: Methenamine + Methylthioninium (Drug)

Methenamine + Methylthioninium

Experimental

Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days

干预措施: Antibiotics (Drug)

Methenamine+Methylthioninium+Acriflavine+Atropa belladona

Active Comparator

Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days

干预措施: Methenamine + Methylthioninium + Acriflavine + Atropa belladona (Drug)

Methenamine+Methylthioninium+Acriflavine+Atropa belladona

Active Comparator

Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days

干预措施: Antibiotics (Drug)

结局指标

主要结局

Urination regularity

时间窗: Following three days of treatment with urinary antiseptics

Percentage of subjects presenting improvement in cystitis symptoms in the "Urination Regularity" domain of the UTISA at Visit 2.

次要结局

  • Problems with Urination at Visit 3(After 6 days of treatment)
  • Total UTISA score(From pretreatment to final visit, total of 6 days of treatment)
  • Adverse events(From pretreatment to final visit, total of 6 days of treatment)
  • UTISA question # 9(At Visit 2, after 3 days of treatment)
  • Blood in Urine at Visit 3(After 6 days of treatment)
  • Problems with Urination at Visit 2(After 3 days of treatment)
  • Pain Associated with UTI at Visit 3(After 6 days of treatment)
  • Blood in Urine at Visit 2(After 3 days of treatment)
  • Pain Associated with UTI at Visit 2(After 3 days of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlos Pereira Nunes

Professor of Internal Medicine

Fundação Educacional Serra dos Órgãos

研究点 (1)

Loading locations...

相似试验